This is the authors' abstract. We don't add key points for this paper.
HbSC disease, the second most common sickle hemoglobinopathy in people of African descent, is caused by compound heterozygosity for sickle hemoglobin (HbS; p.glu7val) and C hemoglobin (HbC; p.glu7lys). One in 800 African Americans have HbSC disease; nearly a quarter of the population of western Nigeria and northern Ghana carry the HbC gene. Compared with the rapidly expanding treatment landscape for sickle cell anemia and HbS-β thalassemia (HbS-only phenotypes), HbSC disease-focused treatment is neither available nor the subject of clinical trials (ClinTrials.gov).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Minniti et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: